Last reviewed · How we verify

NCT04540510: OPEP

OPEP Devices in Acute Inpatient Treatment of Pneumonia

Terminated NA Results posted Last updated 24 September 2021
What this trial tests

NA trial testing OPEP therapy in Community-acquired Pneumonia in 11 participants. Terminated before completion.

Timeline
13 August 2019
Primary endpoint
18 February 2021
18 February 2021

Quick facts

Lead sponsorDanbury Hospital
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment11
Start date13 August 2019
Primary completion18 February 2021
Estimated completion18 February 2021
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Danbury Hospital

Who can join

18 and older, any sex, with Community-acquired Pneumonia. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Length of Hospital Stay Primary · duration of hospital stay, an expected average of 4 days

Number of days that the patient stays in hospital was collected from medical record. We have calculated the mean and the standard deviation for both groups.

GroupValue95% CI
OPEP Therapy Added to Standard Pneumonia Care1.2± 0.9
Standard Pneumonia Care4.0± 1.2
Reported Dyspnea by Modified-Borg Score Secondary · duration of hospital stay, an expected average of 4 days

Dyspnea as measured by modified-Borg score, minimum value 0 (No shortness of breath) and maximum value 10 (Maximal breathlessness). Score scale is from 0-10. We have calculated the mean and the standard deviation for both groups.

GroupValue95% CI
OPEP Therapy Added to Standard Pneumonia Care1.2± 3.8
Standard Pneumonia Care2.4± 2.0
Duration of Antibiotics Secondary · duration of hospital stay, an expected average of 4 days

Duration of antibiotics was collected from medical record. We have calculated the mean and the standard deviation for both groups.

GroupValue95% CI
OPEP Therapy Added to Standard Pneumonia Care8.8± 4.5
Standard Pneumonia Care7.4± 4.3
Duration of Fever Secondary · duration of hospital stay, an expected average of 4 days

Duration of fever was collected from medical record. We have calculated the mean and the standard deviation for both groups.

GroupValue95% CI
OPEP Therapy Added to Standard Pneumonia CareNA± NA
Standard Pneumonia Care0.8± 1.0
Number of Participants With Need for Oxygen Supplement at Hospital Discharge Secondary · duration of hospital stay, an expected average of 4 days

Number of participants with need for oxygen supplement at the time of hospital discharge was collected from medical record for both groups.

GroupValue95% CI
OPEP Therapy Added to Standard Pneumonia Care0
Standard Pneumonia Care0
Reported 30-, 60-, and 90-day Readmission Rates Secondary · 90 day after the hospital discharge

Number of total hospital readmissions post-enrollment was obtained from medical record.

GroupValue95% CI
OPEP Therapy Added to Standard Pneumonia Care0
Standard Pneumonia Care0
Number of Participants With Positive Sputum Culture Secondary · duration of hospital stay, an expected average of 4 days

Data on the diagnosis of organism by sputum (positive sputum culture) was collected from medical record. We have counted number of participants with intervention and without intervention.

GroupValue95% CI
OPEP Therapy Added to Standard Pneumonia Care1
Standard Pneumonia Care3
Number of Participants Transferred to the Intensive Care Unit (ICU) Secondary · duration of hospital stay, an expected average of 4 days

Number of participants transferred to the intensive care unit post enrollment was obtained from medical record for both groups.

GroupValue95% CI
OPEP Therapy Added to Standard Pneumonia Care1
Standard Pneumonia Care1

Sponsor's own description

This is a randomized-controlled prospective study to be conducted at Danbury Hospital and Norwalk Hospital to evaluate oscillatory positive expiratory pressure (OPEP) devices for "airway clearance" (helping to clear out phlegm or mucous from your lungs and bronchial tubes) in the treatment of patients admitted to the hospital with pneumonia. Approximately 200 subjects are expected to participate in this study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Community-acquired Pneumonia

Currently open trials in the same condition.

Other Danbury Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04540510.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing